A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP ...

Schomburg said Eisbach views EIS-12656 as an alternative to poly-ADP-ribose polymerase inhibitors (PARP) inhibitors in therapy for many hard-to-treat cancers. PARP proteins are involved in DNA repair, ...

[48–50] Final data remain to be published. Table 1. Poly-(ADP-ribose) polymerase inhibitors in clinical studies. PARP inhibitor Number of completed or ongoing studies Type of studies completed ...

College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China ...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share.

Daiichi Sankyo has claimed approval in Japan, its home market, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab ...

Arvinas focuses on protein degradation, with its lead candidate, ARV-471, in Phase 3 trials for breast cancer. Read why we ...

No longer reserved for time solely at the gym, the best activewear brands often blend the lines between fashion and function, offering longevity outside of just a sweaty workout. If you need more ...